Skip to main content

Doxorubicin + Trabectedin Tied to Increased Survival in Metastatic Leiomyosarcoma

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 6, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Sept. 5, 2024 -- For patients with metastatic or surgically unresectable leiomyosarcoma, combination therapy with doxorubicin and trabectedin is associated with improved overall and progression-free survival compared with doxorubicin alone, according to a study published online Sept. 4 in the New England Journal of Medicine.

Patricia Pautier, M.D., from the Institut Gustave-Roussy in Villejuif, France, and colleagues conducted a phase 3 trial involving 150 patients with metastatic or unresectable leiomyosarcoma who had not received chemotherapy. Patients were randomly assigned to doxorubicin (six cycles) or doxorubicin plus trabectedin (six cycles), with continued trabectedin as maintenance therapy in patients in the doxorubicin-trabectedin group without disease progression. After six cycles of therapy, surgery was allowed to resect residual disease in each group.

The researchers found that at a median follow-up of 55 months, 47 and 60 patients in the doxorubicin-trabectedin and doxorubicin groups, respectively, had died. Median overall survival was longer in the doxorubicin-trabectedin group versus the doxorubicin group (33 versus 24 months; adjusted hazard ratio for death, 0.65). Progression-free survival was longer in the doxorubicin-trabectedin group versus the doxorubicin group, in a finding consistent with earlier reports (12 versus six months; adjusted hazard ratio for progression or death, 0.37).

"The trial results support the use of doxorubicin plus trabectedin for the first-line treatment of advanced or metastatic leiomyosarcomas, offering hope for improved outcomes in this challenging disease area," the authors write.

The study was partially funded by PharmaMar, the manufacturer of trabectedin.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2024

Read this next

U.S. Cancer Incidence Trends Lower Than Expected in 2021

FRIDAY, Sept. 6, 2024 -- U.S. cancer incidence trends improved in 2021, but continued to be lower than expected, according to a study published online Sept. 6 in JAMA Network...

World Trade Center Exposure Linked to Increased DNA Methylation

THURSDAY, Sept. 5, 2024 -- World Trade Center (WTC) exposure is associated with increased DNA methylation, which may contribute to breast cancer, according to a study published in...

Suicide Risk Higher for Cancer Patients Not Proceeding With Recommended Surgery

WEDNESDAY, Sept. 4, 2024 -- Higher suicide deaths are seen among cancer patients who do not undergo recommended surgery, according to a research letter published online Sept. 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.